CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis

Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine INDIANAPOLIS, Sept. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that th... Biopharmaceuticals, Dermatology, Regulatory Eli Lilly, Incyte , baricitinib, OLUMIANT, atopic dermatitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news